SNDT WOMEN'S UNIVERSITY
BMK Knowledge Resource Centre
Vithaldas Vidyavihar, Juhu Tara Road,
Santacruz (West) Mumbai - 400049
Clinical observation of the transition from short-term intensive insulin therapy to IDegLira combined with metformin in Chinese patients with type 2 diabetes mellitus
Tan Xiaoxia
Clinical observation of the transition from short-term intensive insulin therapy to IDegLira combined with metformin in Chinese patients with type 2 diabetes mellitus - P 195-200
The safety and efficacy of transitioning from short-term
intensive insulin therapy to a regimen of insulin degludec/liraglutide (IDegLira) combined with metformin in
type 2 diabetes mellitus patients is evaluated in the
present study. Conducted at Shenzhen Luohu Hospital
Group, the study involved 81 patients who switched
from continuous subcutaneous insulin infusion to
IDegLira and metformin after four days. Results showed
significant improvements: insulin doses decreased
from 40.28 to 14.79 IU, HbA1c levels fell from 9.94%
to 7.67%, and body weight slightly reduced. The transition also enhanced glycemic control, with reduced
mean glucose and variation, and increased time in
range.
IDegLira
metformin
short-term intensive insulin therapy
type 2 diabetes mellitus
Clinical observation of the transition from short-term intensive insulin therapy to IDegLira combined with metformin in Chinese patients with type 2 diabetes mellitus - P 195-200
The safety and efficacy of transitioning from short-term
intensive insulin therapy to a regimen of insulin degludec/liraglutide (IDegLira) combined with metformin in
type 2 diabetes mellitus patients is evaluated in the
present study. Conducted at Shenzhen Luohu Hospital
Group, the study involved 81 patients who switched
from continuous subcutaneous insulin infusion to
IDegLira and metformin after four days. Results showed
significant improvements: insulin doses decreased
from 40.28 to 14.79 IU, HbA1c levels fell from 9.94%
to 7.67%, and body weight slightly reduced. The transition also enhanced glycemic control, with reduced
mean glucose and variation, and increased time in
range.
IDegLira
metformin
short-term intensive insulin therapy
type 2 diabetes mellitus